CIK 0001393434 · Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-23 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −3,057 | $8.28 | $25K | 323,368 |
| 2026-02-23 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −1,759 | $8.28 | $15K | 330,653 |
| 2026-02-20 | Waheed Nadia Chief Medical Officer | Sale 10b5-1 | −3,510 | $7.74 | $27K | 314,907 |
| 2026-02-20 | LINDSTROM RICHARD L MD Director | Purchase | +60,229 | $7.66 | $461K | 246,933 |
| 2026-02-12 | Notman Donald Chief Operating Officer | Sale | −11,446 | $9.04 | $103K | 366,356 |
| 2026-02-12 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −10,348 | $9.04 | $94K | 332,412 |
| 2026-02-12 | Dugel Pravin See Remarks | Sale 10b5-1 | −124,882 | $9.04 | $1.1M | 3,033,078 |
| 2026-02-12 | Waheed Nadia Chief Medical Officer | Sale 10b5-1 | −7,863 | $9.04 | $71K | 318,417 |
| 2026-02-04 | Notman Donald Chief Operating Officer | Sale | −6,035 | $8.54 | $52K | 377,802 |
| 2026-02-02 | Notman Donald Chief Operating Officer | Sale | −5,455 | $9.14 | $50K | 383,837 |
| 2026-01-21 | Robinson David Wayne Global CCO | Grant or award | +136,000 | 136,000 | ||
| 2026-01-21 | Robinson David Wayne Global CCO | Grant or award · Stock Option (Right to Buy) | +416,000 | 416,000 | ||
| 2026-01-20 | Robins Jason Shand Interim CFO | Grant or award · Stock Option (Right to Buy) | +33,000 | 33,000 | ||
| 2026-01-02 | Anderman Todd Chief Legal Officer | Grant or award | +64,900 | 152,468 | ||
| 2026-01-02 | Anderman Todd Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +197,650 | 197,650 | ||
| 2026-01-02 | Meyers Steve Lawrence Chief Commercial Officer | Grant or award | +64,900 | 217,628 | ||
| 2026-01-02 | Meyers Steve Lawrence Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +197,650 | 197,650 | ||
| 2026-01-02 | Nayak Sanjay Chief Strategy Officer | Grant or award | +64,900 | 342,760 | ||
| 2026-01-02 | Nayak Sanjay Chief Strategy Officer | Grant or award · Stock Option (Right to Buy) | +197,650 | 197,650 | ||
| 2026-01-02 | Kaiser Peter Chief Development Officer | Grant or award | +79,112 | 271,918 |
Page 3 of 8 · 158 trades